Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Eli Lilly shares are now positive for the year, up 10% since the start of January.

Meta c Mark Zuckerberg took the stand on Monday in a historic antitrust trial that could force the tech giant to break off ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...